Mark Sievert
Impact in
-
- Gastric Cancer Management and Outcomes
- Surgery top 10%
- Esophageal Cancer Research and Treatment
- Intraperitoneal and Appendiceal Malignancies
Papers in
-
- Gastric Cancer Management and Outcomes 2
-
- Breast Cancer Treatment Studies 1
- Co-authors
- Akin Atmaca (1 shared paper)Gernot Seipelt (1 shared paper)Salah Eddin Al-Batran (1 shared paper)Claudia Pauligk (1 shared paper)Elke Jäger (1 shared paper)Jan Stoehlmacher (1 shared paper)Nils Homann (1 shared paper)Mary Ann Fritz (1 shared paper)
- Partner nations
- GermanyUnited StatesFrance
In The Last Decade
Mark Sievert
5 papers receiving 814 citations
Mark Sievert's Hit Papers
Peers
Comparison fields: 5 of 23
- Pulmonary and Respiratory Medicine 482
- Surgery 173
- Oncology 42
- Cancer Research 9
- Geriatrics and Gerontology 2
Countries citing papers authored by Mark Sievert
This map shows the geographic impact of Mark Sievert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Sievert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Sievert more than expected).
Fields of papers citing papers by Mark Sievert
This network shows the impact of papers produced by Mark Sievert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Sievert. The network helps show where Mark Sievert may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Sievert, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial Hit paper breakdown → | 2016 | 585 |
| 2 | 2008 | 215 | |
| 3 | 2009 | 15 | |
| 4 | 2008 | 14 | |
| 5 | 2023 | 6 |
About Mark Sievert
Mark Sievert is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research, Hematology, Nuclear Energy and Engineering and Waste Management and Disposal, having authored 5 papers that have together received 835 indexed citations. Recurring topics across this work include Gastric Cancer Management and Outcomes (2 papers), Breast Cancer Treatment Studies (1 paper) and Multiple Myeloma Research and Treatments (1 paper). The work is most often cited by research in Pulmonary and Respiratory Medicine (482 citations), Surgery (173 citations), Oncology (42 citations), Cancer Research (9 citations) and Geriatrics and Gerontology (2 citations). Mark Sievert has collaborated with scholars based in Germany, United States and France. Frequent co-authors include Akin Atmaca, Gernot Seipelt, Salah Eddin Al-Batran, Claudia Pauligk, Elke Jäger, Jan Stoehlmacher, Nils Homann, Mary Ann Fritz, Jörg T. Hartmann and Volker Rethwisch. Their work appears in journals such as Annals of Oncology, Cancer Medicine and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.